-
Je něco špatně v tomto záznamu ?
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic
P. Hradilek, E. Meluzinova, O. Zapletalova, P. Hanulikova, D. Horakova, I. Woznicova, L. Pavliska, I. Stetkarova, M. Valis, P. Stourac, J. Adamkova, R. Ampapa, M. Vachova, J. Mares
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
Odkazy
PubMed
35240415
DOI
10.1016/j.msard.2021.103391
Knihovny.cz E-zdroje
- MeSH
- fingolimod hydrochlorid terapeutické užití MeSH
- lidé MeSH
- natalizumab terapeutické užití MeSH
- retrospektivní studie MeSH
- roztroušená skleróza * chemicky indukované farmakoterapie epidemiologie MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: A special care of MS women planning a pregnancy is highly demanding especially in the terms of disease modifying treatment (DMD) decisions and counselling regarding periods of conception, pregnancy and postpartum period. OBJECTIVE: To provide data about impact of pregnancy, delivery or miscarriage/artificial abortion on MS disease course in Czech women with MS based on analysis of retrospective data from the Czech national registry ReMuS. METHODS: The analysis focused on women with MS with at least one record of pregnancy in the registry. Clinical data (EDSS, relapses) were collected prior to conception, during pregnancy and after delivery or miscarriage/artificial abortion. These data were analysed according to baseline characteristics of DMD treatment prior to conception and according to breastfeeding status. RESULTS: A total of 1 533 pregnancies were analysed from the period of 2013 until 31st December 2019. The occurrence of relapses and worse EDSS was significantly related to the treatment with escalation therapy prior to conception. Relapses were significantly more frequent in women who breastfed less than 3 months than in women who breastfed more than 3 months or did not breastfeed at all. Patients treated with either fingolimod or natalizumab prior to pregnancy were significantly more likely to develop relapses during pregnancy. CONCLUSION: Pregnancy and postpartum period were generally safe for Czech women with MS. Better disease outcomes were observed in those who had been treated with first line injectable DMDs prior to conception and those who either breastfed more than 3 months or did not breastfeed at all. We confirmed the assumption of rebound phenomenon of MS after discontinuation of treatment due to planned pregnancy both for fingolimod and natalizumab.
Department of Neurology Hospital Ceske Budejovice Czech Republic
Department of Neurology Hospital of Jihlava Czech Republic
Department of Neurology KZ a s Hospital Teplice Czech Republic
Department of Neurology University Hospital and Masaryk University Brno Czech Republic
Department of Neurology University Hospital Ostrava Czech Republic
Department of Science and education University Hospital Ostrava Czech Republic
Faculty of Medicine Ostrava University Czech Republic
The Institute for the Care of Mother and Child Prague Faculty of Medicine in Pilsen Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019316
- 003
- CZ-PrNML
- 005
- 20220804135545.0
- 007
- ta
- 008
- 220720s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2021.103391 $2 doi
- 035 __
- $a (PubMed)35240415
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hradilek, Pavel $u Faculty of Medicine, Ostrava University, Czech Republic; Department of Neurology, University Hospital Ostrava, Czech Republic. Electronic address: pavel.hradilek@seznam.cz
- 245 10
- $a Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic / $c P. Hradilek, E. Meluzinova, O. Zapletalova, P. Hanulikova, D. Horakova, I. Woznicova, L. Pavliska, I. Stetkarova, M. Valis, P. Stourac, J. Adamkova, R. Ampapa, M. Vachova, J. Mares
- 520 9_
- $a BACKGROUND: A special care of MS women planning a pregnancy is highly demanding especially in the terms of disease modifying treatment (DMD) decisions and counselling regarding periods of conception, pregnancy and postpartum period. OBJECTIVE: To provide data about impact of pregnancy, delivery or miscarriage/artificial abortion on MS disease course in Czech women with MS based on analysis of retrospective data from the Czech national registry ReMuS. METHODS: The analysis focused on women with MS with at least one record of pregnancy in the registry. Clinical data (EDSS, relapses) were collected prior to conception, during pregnancy and after delivery or miscarriage/artificial abortion. These data were analysed according to baseline characteristics of DMD treatment prior to conception and according to breastfeeding status. RESULTS: A total of 1 533 pregnancies were analysed from the period of 2013 until 31st December 2019. The occurrence of relapses and worse EDSS was significantly related to the treatment with escalation therapy prior to conception. Relapses were significantly more frequent in women who breastfed less than 3 months than in women who breastfed more than 3 months or did not breastfeed at all. Patients treated with either fingolimod or natalizumab prior to pregnancy were significantly more likely to develop relapses during pregnancy. CONCLUSION: Pregnancy and postpartum period were generally safe for Czech women with MS. Better disease outcomes were observed in those who had been treated with first line injectable DMDs prior to conception and those who either breastfed more than 3 months or did not breastfeed at all. We confirmed the assumption of rebound phenomenon of MS after discontinuation of treatment due to planned pregnancy both for fingolimod and natalizumab.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a roztroušená skleróza $x chemicky indukované $x farmakoterapie $x epidemiologie $7 D009103
- 650 _2
- $a natalizumab $x terapeutické užití $7 D000069442
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a retrospektivní studie $7 D012189
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Meluzinova, Eva $u Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Zapletalova, Olga $u Faculty of Medicine, Ostrava University, Czech Republic; Department of Neurology, University Hospital Ostrava, Czech Republic
- 700 1_
- $a Hanulikova, Petra $u The Institute for the Care of Mother and Child, Prague, Faculty of Medicine in Pilsen, Czech Republic
- 700 1_
- $a Horakova, Dana $u Department of Neurology, and Center of Clinical Neuroscience, 1st Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Woznicova, Ivana $u Department of Neurology, University Hospital Ostrava, Czech Republic
- 700 1_
- $a Pavliska, Lubomir $u Department of Science and education, University Hospital, Ostrava, Czech Republic
- 700 1_
- $a Stetkarova, Ivana $u Department of Neurology, 3rd Faculty of Medicine, Charles University in Prague and Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Valis, Martin $u Department of Neurology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic
- 700 1_
- $a Stourac, Pavel $u Department of Neurology, University Hospital and Masaryk University Brno, Czech Republic
- 700 1_
- $a Adamkova, Jana $u Department of Neurology, Hospital Ceske Budejovice, Czech Republic
- 700 1_
- $a Ampapa, Radek $u Department of Neurology, Hospital of Jihlava, Czech Republic
- 700 1_
- $a Vachova, Marta $u Department of Neurology, KZ a.s., Hospital Teplice, Czech Republic
- 700 1_
- $a Mares, Jan $u Department of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Czech Republic
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 59, č. - (2022), s. 103391
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35240415 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135539 $b ABA008
- 999 __
- $a ok $b bmc $g 1822777 $s 1170559
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 59 $c - $d 103391 $e 20211128 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20220720